MedPath

Proteomics for Chronic Disorder of Consciousness

Conditions
Disorder of Consciousness
Registration Number
NCT03611166
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Brief Summary

Following severe traumatic brain injury, patients may remain unconscious for many years. It is the first proteomic analysis comparing differentially expressed proteins between patients with chronic disorder of consciousness and controls so far. The investigators generated accurate lists of proteomes and identified differences at different disease time courses. The obtained results provide new insight into understanding the molecular mechanisms underlying the chronic disorder of consciousness.

Detailed Description

Background: Patients who awake from severely traumatic brain injury (sTBI) may remain unconscious for many years. Although behavioral assessment and functional imaging are currently used as diagnostic tools, the molecular basis underlying chronic condition has yet to be explored.

Objective:To explore the molecular basis and identify novel biomarkers for the diagnosis and prognosis of patients with chronic disorder of consciousness.

Method: Plasma samples were obtained from patients with chronic disorder of consciousness, and healthy volunteers. A coupled isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics approach was used to screen differentially expressed proteins (DEPs) between patients and controls. Potential molecular mechanisms were further discussed through bioinformatics analyses. Candidate proteins were validated by enzyme-linked immunosorbent assay (ELISA).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Patients ages 14 to 65 years old;
  2. Patients had a history of sTBI;
  3. Patients had awakened from a coma (indicating preserved sleep-wake cycles), including vegetative state and minimally consciousness state;
  4. Patients stay unconscious for more than 1 month.
Exclusion Criteria
  1. Patients with acute infectious diseases or liver dysfunction;
  2. Patients with serious diseases such as cardiac or pulmonary problems.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Protein profilingThree months

A coupled isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics approach was used to screen differentially expressed proteins (DEPs) between patients and controls.

Secondary Outcome Measures
NameTimeMethod
Glasgow Outcome Scale (GOS)In one year

A GOS value of \<3 was considered as a bad recovery, while a GOS value of ≥3 was considered as a good recovery.

Coma Recovery Scale-Revised(CRS-R)30 minutes before blood collection

Coma Recovery Scale-Revised (CRS-R) score was used to quantify the severity, which consists of 23 hierarchically arranged items that comprise six subscales addressing auditory, visual, motor, oromotor/verbal, communication, and arousal processes. The lowest item on each subscale represents reflexive activity, whereas the highest items represent cognitively mediated behaviors.

Trial Locations

Locations (1)

Hangzhou Hospital of Zhejiang CAPR

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath